Cinnima 30 Tablet

Introduction

Cinnima is a prescription medication that contains the active ingredient Cinacalcet. It is available under the brand name Cinnima.

Uses

Cinnima is primarily prescribed to treat a condition called hyperparathyroidism in patients with chronic kidney disease who are on dialysis. It helps to lower the levels of parathyroid hormone (PTH) in the body, which can become elevated in these patients.

Dosage and Administration

Cinnima should be taken exactly as prescribed by your healthcare provider. The dosage may vary depending on your individual condition and response to treatment. It is typically taken once daily, with or without food. Follow the instructions provided by your doctor and not exceed the recommended dose.

Mechanism of Action

Cinacalcet, the active ingredient in Cinnima, works by binding to calcium-sensing receptors on the parathyroid gland. This action helps to lower the release of parathyroid hormone (PTH), which in turn reduces the levels of calcium and phosphorus in the blood. By regulating these levels, Cinnima helps to manage hyperparathyroidism in patients with chronic kidney disease on dialysis.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, loss of appetite, headache, and dizziness. These side effects are usually mild and temporary. However, if you experience any severe or persistent side effects, notify your healthcare provider.

In rare cases, Cinnima may cause more serious side effects such as low calcium levels, seizures, and heart rhythm abnormalities. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

Cinnima may interact with certain medications, including calcium supplements, vitamin D supplements, and other medications used to treat hyperparathyroidism. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before taking Cinnima, discuss your medical history and any other medications you are taking with your healthcare provider. Inform your doctor if you have a history of seizures, heart problems, or liver disease.

Cinnima should not be used in patients with low blood calcium levels or a hypersensitivity to Cinacalcet. Avoid using Cinnima if you are pregnant or breastfeeding, as the effects on the fetus or infant are not yet known.

Storage

Cinnima should be stored at room temperature, away from moisture and heat. Keep the medication out of reach of children and pets. Do not use Cinnima if it has expired or if the packaging is damaged.

Patient Tips

• Take Cinnima exactly as prescribed by your healthcare provider. Do not exceed the recommended dose.
• attend regular follow-up appointments with your doctor to monitor your progress and any potential side effects.
• If you miss a dose of Cinnima, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and continue with your regular dosing schedule.
• Do not stop taking Cinnima without consulting your doctor, as it may affect the management of your condition.
• If you have any questions or concerns about Cinnima or its use, speak with your healthcare provider for further guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Cinacalcet 30mg Film-coated tablets (Health Professionals SmPC) Available at:
• Cinacalcet (Drugs.com) [Accessed 1 Jun. 2024] (online) Available at:
• cinacalcet (sensipar) (RX) [Accessed 10 Jun. 2024] (online) Available at:
• Cinacalcet (MedlinePlus) [Accessed 25 Jun. 2024] (online) Available at:
• Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, Nitta K, Fukagawa M. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):2016-2025. doi: 10.1210/clinem/dgac142. [Accessed 27 Jun. 2024] Available at: